natgillin/translations-raw huggingface dataset:
10. 1 Indtagelse af anden medicin Fortæl det til Deres læge, hvis De allerede tager noget af følgende: • Andre lægemidler til at sænke blodtrykket • Smertestillende midler, der kaldes non- steroide inti- inflammatoriske midler (NSAID’ er), f. eks.
Taking other medicines Tell your doctor if you are already taking any of the following: • other medicine to lower blood pressure • painkillers called non-steroidal anti-inflammatory medicine (NSAIDs) eg.
Ibuprofen • Medicin, der indeholder østrogen • Medicin, der indeholder dopamin, metaraminol, methoxamin, adrenalin (epinefrin), hoste - og forkølelsesmidler, der kan indeholde efedrin, fenylefrin
Ibuprofen • medicine containing Estrogen • medicine containing Dopamine, Metaraminol, Methoxamine, Adrenaline (Epinephrine) cough and cold remedies as they may contain Ephedrine, Phenylephrine.
Hvis De tager eller for nylig har taget andre lægemidler, bør De oplyse Deres læge herom, også hvis der er tale om ikke- receptpligtige lægemidler.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Hvordan man tager Doxagamma 4 mg depottabletter og dermed forbundne navne sammen med mad og drikkevarer Doxagamma 4 mg depottabletter og dermed forbundne navne kan tages sammen med eller efter maden.
Taking Doxagamma 4 mg prolonged release tablets and associated names with food and drink Doxagamma 4 mg prolonged release tablets and associated names tablets can be taken with or after food.
Graviditet og amning De må ikke tage Doxagamma 4 mg depottabletter og dermed forbundne navne, hvis De er gravid eller ammer.
Pregnancy and breast-feeding Do not take Doxagamma 4 mg prolonged release tablets and associated names if you are pregnant or breast-feeding.
Bilkørsel og betjening af maskiner Lad være med at køre eller betjene maskineri, hvis De føler dem mindre opmærksom, mens De tager denne medicin.
Driving and using machines Do not drive or operate machinery if you feel less alert while taking this medicine.
Det er mere sandsynligt ved starten af behandlingen, eller hvis Deres læge øger Deres dosis.
This is more likely at the start of treatment or if the doctor increases your dose.
Følg Deres læges henvisninger og lad være med selv at ændre dosis.
Follow your doctor’ s instructions and do not change the dose yourself.
• Synk tabletterne hele med et helt glas vand • Kan tages med eller uden mad • Tabletterne må ikke tygges, brækkes over eller knuses
• Swallow the tablets whole with a full glass of water • Take with or without food • Do not chew, break or crush the tablets.
Voksne inklusive ældre Den sædvanlige startdosis er én Doxagamma 4 mg depottabletter og dermed forbundne navne tablet én gang daglig.
Adults including the elderly The usual starting dose is one Doxagamma 4 mg prolonged release tablets and associated names tablet once a day.
Om nødvendigt kan Deres læge øge denne dosis til den maksimale på to tabletter én gang om dagen Til behandling af hypertension kan Deres læge give Dem anden medicin, der skal tages sammen med Doxagamma 4 mg depottabletter og dermed forbundne navne.
To treat hypertension, your doctor may give you another medicine to take along with Doxagamma 4 mg prolonged release tablets and associated names.
Deres tabletter med ’ modificeret frigivelse ’ er specielt udformet til langsom frigivelse af lægemidlet fra tabletskallen, Skallen nedbrydes ikke, men passerer igennem kroppen.
Your ‘ modified release’ tablets have been specially designed to slowly release the medicine from the tablet shell.
Den tomme tablet vil blive
The shell does not break down but passes through your body.
24/ 26 udskilt i Deres affføring.
The empty tablet will be passed out in your stools.
Hvis De tager flere Doxagamma 4 mg depottabletter og dermed forbundne navne, end De bør Kontakt Deres læge eller skadestuen på det nærmeste hospital med det samme.
If you take more Doxagamma 4 mg prolonged release tablets and associated names than you should Contact your doctor or nearest hospital casualty department immediately.
Som alle andre lægemidler kan Doxagamma 4 mg depottabletter og dermed forbundne navne have bivirkninger, selvom ikke alle får bivirkninger.
4 POSSIBLE SIDE EFFECTS
Almindelige bivirkninger, der ses hos mere end 1 patient ud af 100, omfatter:
Like all medicines, Doxagamma 4 mg prolonged release tablets and associated names can cause side effects, although not everybody gets them.
Usædvanlige bivirkninger, der ses hos færre end 1 patient ud af 1. 000, men hos færre end 1 ud af 100 patienter, omfatter:
Common side effects, seen in more than 1 in 100 patients but less than 1in 10, include dizziness, giddiness, feeling unusually tired or generally unwell, swelling of the ankles, palpitations, headache, chest pain, sleepiness, muscle cramp, constipation, indigestion, breathlessness, runny nose, delayed ejaculation, frequent urge to pass urine and blurred vision.
Opsvulmen af of ansigt og krop, følelse af svaghed, kolde fingre og tær, svimmelhed ved at stå op, en hurtig eller uregelmæssig hjerterytme, en langsom hjerterytme, angina, kraftige brystsmerter, besvær med vejrtrækningen, tremor, muskelstivhed, svaghed eller smerter, smertende eller opsvulmede led, ændring i appetitten, hårtab, næseblod, hoste, ondt i opsvulmet hals, lave kaliunniveauer, følelse af tørst, podagra, mareridt, hukommelsestab, humørskift, tab af blærekontrol, eller mindre hyppig trang til at lade vandet, ringen for ørerne og smagsændringer.
Uncommon effects, seen in more than 1 out of 1,000 patients but less than 1 in 100 patients, include swelling of the face and body, feeling faint, cold fingers and toes,, dizziness on standing, a racing or irregular heart beat, a slow heart beat, angina, severe chest pain, difficulty breathing, tremor, muscle stiffness, weakness or pain, pain or swelling of joints, change in appetite, hair loss, nose bleeds, cough, sore swollen throat, low blood potassium levels, feeling thirsty, gout, nightmares, loss of memory, mood changes, loss of bladder control or less frequent urge to pass urine, ringing in the ears and changes in taste.
Sjældne bivirkninger, der ses hos flere end 1 patient ud af 10. 000. menn færre end 1 ud af 1. 000, omfatter depression, følelse af rastløshed, stikken og prikken, et allergisk udslæt, kløende rød hud, mavesmerter, diaré, værende syg, en hæs stemme, besvimelse, tab af bevidsthed, gulsot, leverforandringer, lavt blodsukker, impotens, vedvarende erektion.
Rare side effects, seen in more than 1 in 10,000 patients but less than 1 out of 1,000, include depression, feeling restless, pins and needles, an allergic rash, itchy red skin, stomach pain, diarrhoea, being sick, a hoarse voice, fainting, loss of consciousness, jaundice, liver changes, low blood sugar, impotence, persistent erection.
Meget sjældne bivirkninger ses hos mindre end 1 ud af 10. 000 patienter omfatter ændringer i blodet og en stigning i blod - og creatininniveauer.
Very rare effects seen in less than 1 in 10,000 patients include blood changes and an increase in blood and creatinine levels.
5 HVORDAN DE OPBEVARER DOXAGAMMA 4 MG DEPOTTABLETTER OG DERMED FORBUNDNE NAVNE:
5 HOW TO STORE DOXAGAMMA 4 MG PROLONGED RELEASE TABLETS AND ASSOCIATED NAMES
25/ 26 Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.
This medicinal product does not require any special storage conditions.
Hvad Doxagamma 4 mg depottabletter og dermed forbundne navne indeholder
6 FURTHER INFORMATION What Doxagamma 4 mg prolonged release tablets and associated names contains
- Det aktive stof er 4 mg doxazosin som doxazosinmesilat).
- The active substance is 4 mg of doxazosin as doxazosin mesilate.
butylhydroxytoluen (E321), α- Tocopherol, kolloidalt vandfrit silica, natriumstearyl fumarat, methacrylsyre copolymer og titaniumdioxid (E171).
(E321), alpha-tocopherol, anhydrous colloidal silica, sodium stearyl fumarate, methacrylic acid copolymer and titanium dioxide (E171)
Hvordan Doxagamma 4 mg depottabletter og dermed forbundne navne ser ud og pakningsstørrelsen Doxagamma 4 mg depottabletter og dermed forbundne navne tabletter er hvide, runde, bikonvekse tabletter med “ DL ” påtrykt.
What Doxagamma 4 mg prolonged release tablets and associated names looks like and contents of the pack Doxagamma 4 mg prolonged release tablets and associated names tablets are white, round, biconvex tablets with bossing “ DL”.
De findes i PVC/ PVDC/ aluminium blisterpakninger, der indeholder 28 tabletter [10, 20, 30, 50, 56, 60, 90, 98, 100, 140 (10x14) tabletter og i HDPE tabletbeholdere med 100, 250 tabletter.
They are available in PVC/ PVDC/ aluminium blisters packs of 28 tablets [10, 20, 30, 50, 56, 60, 90, 98, 100, 140 (10 x 14) tablets and in HDPE tablet containers of 100, 250 tablets].
Dette lægemiddel er godkendt i EEA medlemslandene under følgende navne:
This medicinal product is authorised in the Member States of the EEA under the following names:
[Udfyldes ved afslutningen af proceduren]
[See Annex I - To be completed nationally]
London, 11/ 10/ 2006 EMEA/ CHMP/ 423308/ 2006
London, 11/ 10/ 2006 EMEA/ CHMP/ 423308/ 2006
21, OM Doxagamma ” 4 mg depottabletter og tilknyttede navne Internationalt fællesnavn (INN):
OPINION FOLLOWING AN ARTICLE 29(2)1 REFERRAL FOR Doxagamma 4 mg prolonged release tablets and associated names International Non-Proprietary Name (INN):
Doxagamma 4 mg depottabletter og tilknyttede navne (doxazosin) er et alfa- 1- receptor- blokerende stof, som anvendes til behandling af patienter med essentiel hypertension og til symptomatisk behandling af benign prostatahyperplasi.
Doxagamma 4 mg prolonged release tablets and associated names (doxazosin) is a receptor alfa blocking agent used in the treatment of patients with essential hypertension and in the symptomatic treatment of patients with benign prostatic hyperplasia.
Referencemedlemsstaten var Danmark og den berørte medlemsstat var:
The Reference Member State was Denmark and the Concerned Member States were:
Formålet med indbringelsen var at opnå enighed om, hvor vidt frigivelsesprofilen for Doxagamma 4 mg depottabletter afviger væsentligt fra det oprindelige lægemiddel og eventuelt medfører øget forekomst af bivirkninger såsom svimmelhed og hypotension, hvorvidt der er væsentlige forskelle i resultaterne af testbatcher i enkeltdosisfasen af undersøgelserne 5208 og 1995 og hvor vidt ansøgeren ved udformningen af bioækvivalensundersøgelserne afviger fra CHMP’ s retningslinjer, navnlig når det gælder virkningen af fødevarer.
The scope of the referral was to agree whether Doxagamma 4mg prolonged release tablets differ significantly with regards to the release profile from the originator product with potential for increased incidence of adverse events such as dizziness and hypotension, whether there were significant differences in performance of test batches in the single dose phase of studies 5208 and 1995 and whether the applicant has deviated from CHMP guidelines on the design of the bioequivalence studies, particularly in relation to the effect of food.
I lyset af de samlede data, der var blevet fremlagt, og den faglige debat i udvalget var CHMP på sit møde i juni 2006 af den opfattelse, at benefit- risk forholdet er gunstigt for Doxagamma 4 mg depottabletter og tilknyttede navne, at de rejste indvendinger ikke bør forhindre udstedelse af en markedsføringstilladelse, og at referencemedlemsstatens produktresumé, etikettering og indlægsseddel bør ændres.
During the June 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Doxagamma 4 mg prolonged release tablets and associated names, that the objections raised should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
FORTEGNELSE OVER LÆGEMIDLETS/ LÆGEMIDLERNES NAVNE, LÆGEMIDDELFORM( ER), STYRKE( R), INDGIVELSESVEJ( E), ANSØGER( E), INDEHAVER( E) AF MARKEDSFØRINGSTILLADELSE I MEDLEMSSTATERNE
LIST OF THE NAMES, PHARMACEUTICAL FORM(S), STRENGTH(S) OF THE MEDICINAL PRODUCT(S), ROUTE(S) OF ADMINISTRATION, APPLICANT(S) MARKETING AUTHORISATION HOLDER(S) IN THE MEMBER STATES
1/ 23 Medlemsstat
1/ 24
2- 18, 61118 Bad Vilbel Tyskland Tlf.:
2-18, 61118 Bad Vilbel Germany Tel:
Doxalfa 4 mg pailginto 4 atpalaidavimo tabletės
Doxalfa 4 mg pailginto 4 mg atpalaidavimo tabletė s
Nieuwe Donk 9, 4879 AC Etten- Leur Nederlandene Tlf.:
Nieuwe Donk 9, 4879 AC Etten-Leur The Netherlands Tel:
Doxazosine retard CF 4mg, tabletten met gereguleerde afgifte
Doxazosine retard CF 4 mg 4mg, tabletten met gereguleerde afgifte
2/ 23 Spanien
2/ 24
Frederic Mompou, 5 08960 Sant Just Desvern Barcelona Spanien Tlf.:
Barcelona, Spain Tel:
Doxastad 4mg depottablett
Doxastad 4mg depottablett
Genus Pharmaceuticals Benham Valence, Speen, Newbury, Berkshire RG20 8LU Tlf.:
Genus Pharmaceuticals Benham Valence, Speen, Newbury, Berkshire RG20 8LU Tel:
3/ 23 BILAG II
3/ 24 ANNEX II
4/ 23 FAGLIGE KONKLUSIONER
4/ 24 SCIENTIFIC CONCLUSIONS
SAMLET RESUMÉ AF DEN FAGLIGE VURDERING AF Doxastad 4 mg depottabletter og de tilknyttede navne (se bilag I)
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF Doxastad 4 mg prolonged release tablets and associated names (see Annex I)
BEGRUNDELSER FOR ÆNDRING AF PRODUKTRESUMÉ( ER), ETIKETTERING OG INDLÆGSSEDDEL
GROUNDS FOR AMENDMENT OF THE SUMMARY(IES) OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET
- hensigten med indbringelsen var at opnå enighed om, hvor vidt frigivelsesprofilen for
- The scope of the referral was to agree whether Doxastad 4mg prolonged release tablets differ
Doxastad 4 mg depottabletter og de tilknyttede navne afviger væsentligt fra det oprindelige lægemiddel og eventuelt medfører øget forekomst af bivirkninger såsom hypotension og svimmelhed, hvorvidt der er væsentlige forskelle i resultaterne af testbatcher i enkeltdosisfasen af undersøgelserne 5208 og 1995, hvor vidt ansøgeren ved udformningen af bioækvivalensundersøgelserne afviger fra CHMP’ s retningslinjer, navnlig når det gælder virkningen af fødevarer, og spørgsmålet om, hvorvidt denne afvigelse medfører, at undersøgelserne ikke er tilstrækkeligt følsomme til at kunne registrere forskelle mellem præparaterne,
significantly with regards to the release profile from the originator product with potential for increased incidence of adverse events such as dizziness and hypotension, whether there were significant differences in performance of test batches in the single dose phase of studies 5208 and 1995 and whether the applicant has deviated from CHMP guidelines on the design of the bioequivalence studies, particularly in relation to the effect of food with concern regarding the adequate sensitivity of to detect a difference between products,
Produktresumé, etikettering og indlægsseddel fremgår af bilag III.
the documentation submitted, the scientific discussion within the Committee and the new wording proposed in the updated Guideline on SPC dated October 2005 and the latest QRD template, the CHMP has recommended the granting of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Doxastad 4 mg prolonged release tablets and associated names (see Annex I).
5/ 23 BILAG III
5/ 24 ANNEX III
6/ 23 PRODUKTRESUME
6/ 24 SUMMARY OF PRODUCT CHARACTERISTICS
7/ 23 1 LÆGEMIDLETS NAVN
7/ 24 1 NAME OF THE MEDICINAL PRODUCT
Doxastad 4 mg depottabletter og dermed forbundne navne [se Bilag I]
Doxastad 4 mg prolonged release tablets and associated names [See Annex I]
Depottablet Hvide, runde bikonvekse tabletter med påtrykt “ DL ” på den ene side.
Prolonged-release tablet White, round, biconvex tablets, with bossing “ DL” on one side.
Symptomatisk behandling af benign prostatahyperplasi.
4 CLINICAL PARTICULARS
4. 2 Dosering og indgivelsesmåde
4.1 Therapeutic indications
Symptomatisk behandling af benign prostatahyperplasi:
Doxastad 4 mg prolonged release tablets and associated names can be used as monotherapy or in combination with another medicinal product e. g. a thiazide diuretic, a beta-adrenoceptor blocking agent, a calcium antagonist or an ACE-inhibitor if either of them alone does not provide sufficient effect.
8/ 23 Samme anbefalinger for dosering som for voksne.
Same dosage recommendations as for adults.
Da der ikke findes klinisk erfaring med patienter med svær leverinsufficienss, anbefales anvendels ikke til disse patienter (se pkt 4. 4).
Since no clinical experience from patients with severe hepatic insufficiency exists, use in these patients is not recommended (see section 4.4).
Der er ikke tilstrækkelige data til at kunne anbefale anvendelse hos børn og unge.
There are not sufficient data to recommend the use in children and adolescents.
- Overfølsomhed over for det active indholdsstof, andre quinazoliner (f. eks. prazosin,
Hypersensitivity to the active substance, other quinazolines (e. g. prazosin, terazosin) or to any of the excipients.
terazosin) eller over for hjælpestofferne.
-
- Anamnese med øsofageal eller gastrointestinal obstruktion eller bedømt som værende udsat
History of oesophageal or gastrointestinal obstruction or judged to be at increased risk for such obstruction.
for øget risiko for sådanne obstruktioner.
-
- Benign prostatahyperplasi og samtidig obstruction af urinafløb, kroniske urinvejsinfektioner
Benign prostatic hyperplasia and concomitant urinary outflow obstruction, chronic urinary tract infections or bladder stones
eller blæresten.
-
- Overflow af blæren, anuri eller progressiv nyreinsufficiens
Overflow bladder, anuria or progressive renal insufficiency
Unormal kort transporttid gennem mave- tarmkanalen kan lede til ufuldstændig absorption.
Abnormally short transport time through the gastrointestinal tract could lead to incomplete absorption.
For at minimere den mulige risiko for posturale virkninger bør patienten - som ved andre antihypertensiver, inklusive alfa- blokerende midler - overvåges ved indledningen af behandlingen..
As for other antihypertensives, including alpha-blocking agents, the patient should be monitored on initiation of therapy to minimise the potential risk for postural effects.
4. 5).
Simultaneous administration of sildenafil or other PDE-5 inhibitors to patients taking alpha-blocker therapy may lead to symptomatic hypotension in some patients (see section 4.5).
Som ved andre vasodilaterende antihypertensiver anbefales der forsigtighed i henhold til medicinsk praksis hos patienter med følgende akutte hjertesygdomme:
As for other vasodilating antihypertensives, caution is recommended according to medical praxis, in patients with the following acute heart diseases:
- Lungeødem som et resultat af aorta - eller mitralstenose
- pulmonary oedema as a result of aortic or mitral stenosis
- Hjertesvigt ved højt output
- heart failure at high output
- Venstre - eller højresidig hjertesvigt som et resultat af lungeemboli, perikardial effusion,
- left or right sided heart failure as a result of pulmonary embolism, pericardial effusion, high
højt output eller lavt fyldningstryk
output or low filling pressure
5. 2).
Doxazosin, as other medicinal products metabolised by the liver, should be administered with caution in patients with signs of minor to moderate hepatic impairment (see section 5.2).
Anvendelse under amning Undersøgelser på dyr har vist, at doxazosin akkumuleres i modermælk.
Use during lactation Animal studies have shown that doxazosin accumulates in breast milk.
Doxazosin forstærker den blodtrykssænkende virkning af andre antihypertensiver.
9/ 24 4.5 Interactions with other medicinal products and other forms of interaction Doxazosin potentiates the blood pressure lowering effect of other antihypertensives.
9/ 23 Non- steroide antirheumatika eller østrogener kan nedsætte doxasosins antihypertensive virkning..
Non-steroidal antirheumatics or estrogens may reduce the antihypertensive effect of doxazosin.
Doxazosin kan have inflydelse på plasma- renin- aktiviteten og på udskillelsen af vanillylmandelinsyre i urin.
Doxazosin may influence the plasma renin activity and urinary excretion of vanillylmandelic acid.
Samtidig administration af sildenafil eller andre PDE- 5 hæmmere til patienter, der er i behandling med alfa- blokkere, kan lede til symptomatisk hypotension hos nogle patienter.
Simultaneous administration of sildenafil or other PDE-5 inhibitors to patients taking alpha-blocker therapy may lead to symptomatic hypotension in some patients.
4. 4).
Therefore, sildenafil doses above 25 mg should not be taken within 4 hours of taking an alpha-blocker (see section 4.4).
De følgende bivirkninger er blevet rapporteret i kontrollerede kliniske forsøg med doxaszosin - depottabletter.
The following undesirable effects have been reported in controlled clinical trials with doxaszosin prolonged-release tablets.
Som mindste kriterium for de anførte bivirkninger gælder, at bivirkningerne anses for muligvis at være relateret til behandlingen.
The adverse reactions considered at least possibly related to treatment are listed below by body system organ class and absolute frequency.
Gastrointestinale sygdomme
Gastrointestinal disorders Common Diarrhoea, nausea, vomiting, gastritis.
Diaré, kvalme, opkastning, gastrit.
10/ 24 General disorders Common
Almene lidelser Almindelig
Headache, fatigue, malaise, oedema, somnolence, asthenia, mouth dryness.
Hovedpine, træthed, utilpashed, ødem, somnolens, astheni, mundtørhed.
Rare cases of syncope in association with orthostatic hypotension have been observed.
10/ 23 Følgende bivirkninger er blevet rapporteret ved klinisk brug af tabletter med umiddelbar frigørelse af doxazosin:
The following adverse events have been reported in clinical use of immediate release tablets of doxazosin:
Thrombocytopeni, leukopeni.
Thrombocytopenia, leukopenia.
Podagra.
Gout.
Nervøsitet.
Nervousness.
Hjertesygdomme:
Cardiac disorderst:
Arytmi, takykardi, palpitationer, angina pectoris, myokardieinfarkt.
Arrhythmia, tachycardia, palpitations, angina pectoris, myocardial infarction.
Cerebrovaskulære hændelser.
Cerebrovascular accidents.
Dyspnøe, hoste, bronchiespasmer, epistaxis.
Dyspnoea, cough, bronchial spasms, epistaxis.
Anorexi, obstipation, øget appetit Sygdomme i lever og galdeveje:
Hepatobiliary disorders:
Ikterus, forhøjede lever transaminaser.
Icterus, increased liver transaminases.
Udslæt, pruritus, purpura.
Rash, pruritus, purpura.
Myalgi, arthralgi, muskelkramper.
Myalgia, arthralgia, muscle cramps.
Øget diurese, haematuri, urin inkontinens.
Increased diuresis, haematuria, urinary incontinence.
Priapisme og impotens.
Priapism and impotence.
Brystsmerter, agitation, ansigtsrødmen.
Chest pain, agitation, facial flushing.
Toksicitet Der er begrænsede data om virkningen af overdosering.
Toxicity There is limited data on the effect of overdoses.
Synkope forekom hos en fastende voksen, der havde taget doxazosin 16 mg.
Syncope occurred in a fasting adult who had taken doxazosin 16 mg.
En 13- årig oplevede moderat intoksikation efter en maksimal dosis på 40 mg doxazosin.
A 13-year-old experienced moderate intoxication following a maximum dose of doxazosin 40 mg.
Sænk hovedets stilling, giv intravenøse væsker og om nødvendigt vasopressorer (for eksempel noradrenalin eller efedrin).
In cases of hypotension: lower the head position, provide intravenous fluids and if needed vasopressors (for instance noradrenaline or ephedrine).
C02CA04
Alpha-adrenoreceptor antagonists
Det generiske navn for det active indholdsstof i Doxastad 4 mg depottabletter og dermed forbundne navne er doxazosin, der er et quinazolinderivat.
C02CA04 The generic name for the active substance in Doxastad 4 mg prolonged release tablets and associated names is doxazosin, which is a quinazoline derivative.
Doxazosin har en vasodilaterende virkning gennem selektiv og kopetitiv blokering af postsynaptiske alfa- 1- receptorer.
Doxazosin has a vasodilating effect through selective and competitive blocking of postsynaptic alpha-1-receptors.